Cite
Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer.
MLA
Fukudo, Masahide, et al. “Population Pharmacokinetics/Pharmacodynamics of Erlotinib and Pharmacogenomic Analysis of Plasma and Cerebrospinal Fluid Drug Concentrations in Japanese Patients with Non-Small Cell Lung Cancer.” Clinical Pharmacokinetics, vol. 52, no. 7, July 2013, pp. 593–609. EBSCOhost, https://doi.org/10.1007/s40262-013-0058-5.
APA
Fukudo, M., Ikemi, Y., Togashi, Y., Masago, K., Kim, Y. H., Mio, T., Terada, T., Teramukai, S., Mishima, M., Inui, K.-I., & Katsura, T. (2013). Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer. Clinical Pharmacokinetics, 52(7), 593–609. https://doi.org/10.1007/s40262-013-0058-5
Chicago
Fukudo, Masahide, Yasuaki Ikemi, Yosuke Togashi, Katsuhiro Masago, Young Hak Kim, Tadashi Mio, Tomohiro Terada, et al. 2013. “Population Pharmacokinetics/Pharmacodynamics of Erlotinib and Pharmacogenomic Analysis of Plasma and Cerebrospinal Fluid Drug Concentrations in Japanese Patients with Non-Small Cell Lung Cancer.” Clinical Pharmacokinetics 52 (7): 593–609. doi:10.1007/s40262-013-0058-5.